Information Provided By: 
Fly News Breaks for December 13, 2016
AKRX
Dec 13, 2016 | 07:07 EDT
Jefferies analyst David Steinberg says the completion of FDA re-inspection at the Decatur sterile injectables manufacturing facility represents a "key event" for Akorn and "reduces a major overhang." The events "clears the path for many product approvals from this plant," Steinberg tells investors in a research note. The analyst views Akorn shares as undervalued and keeps a Buy rating on the name with a $24 price target.
News For AKRX From the Last 2 Days
There are no results for your query AKRX
